<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004690</url>
  </required_header>
  <id_info>
    <org_study_id>199/13316</org_study_id>
    <secondary_id>CELLEGY-FDR001278</secondary_id>
    <nct_id>NCT00004690</nct_id>
  </id_info>
  <brief_title>Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellegy Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the safety and efficacy of monolaurin cream versus a placebo vehicle&#xD;
      cream in suppressing the signs of nonbullous congenital ichthyosiform erythroderma.&#xD;
&#xD;
      II. Assess the incidence of posttreatment rebound or recrudescence in patients with&#xD;
      congenital ichthyosis.&#xD;
&#xD;
      III. Evaluate the long term safety of monolaurin cream with whole body application in these&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a three month, randomized, double blind, placebo controlled study&#xD;
      followed by a nine month, open label, rollover study.&#xD;
&#xD;
      Patients are treated either with a placebo vehicle cream or the study cream, monolaurin (15%&#xD;
      glyceryl monolaurate), for 3 months followed by a four week break. Medications are applied&#xD;
      uniformly twice daily (morning and at least 1 hour before bedtime). After this blinded&#xD;
      portion of the study, all patients are administered monolaurin cream for 9 months.&#xD;
&#xD;
      Patients are followed for 4 weeks after the last cream application.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1996</start_date>
  <completion_date>September 1998</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>90</enrollment>
  <condition>Ichthyosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>monolaurin cream</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Nonbullous congenital ichthyosiform erythroderma (chronic, multifactorial,&#xD;
             hyperkeratotic, inflammatory skin disease) Clinical criteria includes: - generalized&#xD;
             involvement with no flexural sparing - congenital onset usually as collodion baby&#xD;
             (i.e., a taut, shiny encasement which is shed postnatally revealing underlying&#xD;
             erythroderma and generalized ichthyosis) - scales should be fine, whitish, and rather&#xD;
             loose except on the lower legs where the scales may be large, platelike, and dark - if&#xD;
             severely effected: intense erythema is present; overt ectropion may be present;&#xD;
             cicatricial alopecia may be present; and secondary nail dystrophies with thickening of&#xD;
             nail plate and ridging may be present&#xD;
&#xD;
          -  Phenotypically consistent with diagnostic grading photos&#xD;
&#xD;
          -  Grade of at least 3 for scaling on four treatment sites&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Biologic therapy: Not specified&#xD;
&#xD;
          -  Chemotherapy: Not specified&#xD;
&#xD;
          -  Endocrine therapy: At least 4 weeks since prior corticosteroids No concurrent&#xD;
             corticosteroids&#xD;
&#xD;
          -  Radiotherapy: Not specified&#xD;
&#xD;
          -  Surgery: Not specified&#xD;
&#xD;
          -  Other: At least 4 weeks since any prior investigational medications At least 4 weeks&#xD;
             since any prior systemic therapy, such as hypolipidemics or retinoids Nonglycerin&#xD;
             emollients allowed up to 1 week prior to study At least 4 weeks since any other&#xD;
             topical therapy including humectants such as urea, alpha hydroxy or alpha ketoacid&#xD;
             preparations and retinoids No concurrent topical therapy No concurrent investigational&#xD;
             medications&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 months and over&#xD;
&#xD;
          -  Performance status: Not specified&#xD;
&#xD;
          -  Hematopoietic: No clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Hepatic: No clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Renal: No clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Other: Triglyceride or total cholesterol no greater than 3 times normal Must be in&#xD;
             general good health No known hypersensitivity to any component of this study&#xD;
             medication Not pregnant or nursing Adequate contraception required of all fertile&#xD;
             women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl R. Thornfeldt</last_name>
    <role>Study Chair</role>
    <affiliation>Cellegy Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>March 1999</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>dermatologic disorders</keyword>
  <keyword>ichthyosis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ichthyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Monolaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

